November 7, 2018 6:52am
Athersys (ATHX) jumped +$0.01 before announcing a net loss of $9.7 M or $0.07 net loss per share, while ending the Q with cash position of $48 M. Until 12/6/18 Healios’ option is negotiation of the collaboration is completed, it’s still a question?
Audentes Therapeutics (BOLD) closed up +$0.43 before reporting a loss of $36.3 M or -$0.97 per share. The results did not meet “street” expectations for a loss of $0.88 per share.
Bellicum Pharmaceuticals (BLCM) closed down -$0.05 to $4.52 before reporting a net loss of $23.8 or -$0.55 per share. The expectation “beat” results were estimated to be -$0.57.
Global Blood Therapeutics (GBT) jumped +$1.12 before reporting a net loss of $43.1 M or -$0.83 per share compared with $28.6 M or -$0.66 per share for Q3/17. The results surpassed “street” expectations was for a loss of $0.84 per share.
Members only. Please login.